Schedule 13D ownership disclosure
ENTASIS THERAPEUTICS HLDGS I
Security class unavailable · CUSIP: 293614103
Event date: 2019-01-04
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 12.4000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-19-006220
- Form type
- SC 13D
- Filer
- Clarus Lifesciences III, L.P.
- CIK
- CIK 1597143
- Filed
- Jan 11, 2019
- Reporting period
- Jan 04, 2019
- Description
- Schedule 13D beneficial ownership